Recro Reports Third Quarter 2020 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/17/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Recro Pharma (REPH) Tops Q3 EPS by 11c, Revenues Beat
November 9, 2020 7:10 AM ESTRecro Pharma (NASDAQ: REPH) reported Q3 EPS of ($0.09), $0.11 better than the analyst estimate of ($0.20). Revenue for the quarter came in at $19.29 million versus the consensus estimate of $16.33 million.
We continue to deliver superior manufacturing and development services to our customers as their projects grow and evolve, said Gerri Henwood, President and Chief Executive Officer. And since the launch of our Clinical Trials Materials (CTM) and Logistics business in late June, we have seen... More
